Labiana Health Past Earnings Performance
Past criteria checks 0/6
Labiana Health has been growing earnings at an average annual rate of 50.5%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been declining at an average rate of 1.7% per year.
Key information
50.5%
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -1.7% |
| Return on equity | -131.9% |
| Net Margin | -7.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Labiana Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 60 | -4 | 29 | 0 |
| 30 Sep 23 | 60 | -7 | 29 | 0 |
| 30 Jun 23 | 60 | -10 | 28 | 0 |
| 31 Mar 23 | 60 | -9 | 28 | 0 |
| 31 Dec 22 | 61 | -9 | 28 | 0 |
| 31 Dec 21 | 59 | -2 | 27 | 0 |
Quality Earnings: 8RK is currently unprofitable.
Growing Profit Margin: 8RK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 8RK's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 8RK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8RK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 8RK has a negative Return on Equity (-131.92%), as it is currently unprofitable.